Abstract PD17-05: Development and Validation of a Composite Biomarker Predictive of Palbociclib + Endocrine Treatment Benefit in Early Breast Cancer: PENELOPE-B and PALLAS Trials
Abstract P5-02-17: Prognostic and predictive role of RBsig and CCNE1/RB1 gene-expression signatures in patients with advanced breast cancer treated with palbociclib in combination with endocrine therapy in the PALOMA-2 and 3 trials
53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
ASH 2022: 4265: Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
Case Study Workshop: Diffuse Large B-Cell Lymphoma Of The Testis And Cns With Aberrant Co-Expression Of Cd10, Bcl6 And Mum1/Irf4, Abc-Gep, Mcd/C5 Genetic Subtype And Irf4 Alteration
Mutational And Gene Expression Profiling Of Blastic Plasmacytoid Dendritic Cell Neoplasm Reveals Two Distinct Age-Dependent Subgroups And A Role For Clonal Hematopoiesis In Elderly Patients